Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells

Biochimica Et Biophysica Acta
Ning XuP Nilsson-Ehle

Abstract

Apolipoprotein M (apoM) is a novel apolipoprotein presented mostly in high-density lipoprotein (HDL) in human plasma, and is exclusively expressed in liver and in kidney. The pathophysiological function of apoM has not yet been elucidated. Apolipoprotein B (apoB), the characteristic apolipoprotein of low-density lipoprotein (LDL), is like apoM, a very hydrophobic protein, and thereafter they both must co-circulate with lipoprotein particles in plasma. The cytokine, transforming growth factor-beta (TGF-beta), has been shown to decreased apoB secretion in HepG2 cells, and we hypothesized that TGF-beta may have the same effects on apoM expression in HepG2 cells. In the present study, we used real-time RT-PCR to analyze apoM and apoB mRNA levels during administration of TGF-beta, as well as TGF-alpha, epidermal growth factor (EGF) and hepatic growth factor (HGF). TGF-beta significantly inhibited both apoM and apoB mRNA expression in HepG2 cells. The inhibitory effects of TGF-beta were dose-dependent, i.e. 1 ng/ml of TGF-beta decreased apoM mRNA levels by 30%, and 10 or 100 ng/ml of TGF-beta decreased apoM mRNA levels more than 65%. The effect of TGF-beta on apoB mRNA expression was slightly weaker than that of apoM, with a maximum ...Continue Reading

References

Jul 15, 1992·Biochemical and Biophysical Research Communications·W L BlakeG W Melchior
Apr 6, 1995·Biochimica Et Biophysica Acta·G SkrettingH Prydz
Nov 15, 1994·Biochemical and Biophysical Research Communications·E LevyD Ménard
May 1, 1997·Journal of the Neurological Sciences·F BaskinR N Rosenberg
May 15, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M KaiboriT Okumura
Feb 2, 1999·The Journal of Clinical Investigation·M TaharaT Nakamura
Oct 26, 1999·The Journal of Biological Chemistry·N Xu, B Dahlbäck
Nov 4, 2000·Biochimica Et Biophysica Acta·E RassartR Milne
Mar 7, 2001·Frontiers in Bioscience : a Journal and Virtual Library·V I ZannisD Kardassis
Apr 12, 2002·Biochemical and Biophysical Research Communications·Ning XuPeter Nilsson-Ehle
Jun 18, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Esther LutgensMat J A P Daemen

❮ Previous
Next ❯

Citations

Sep 28, 2010·Journal of Molecular Neuroscience : MN·Dongxue ZhaoShumin Deng
Jul 7, 2011·Lipids in Health and Disease·Xiaoying ZhangNing Xu
Oct 6, 2004·Lipids in Health and Disease·Guanghua LuoNing Xu
Sep 18, 2010·Lipids in Health and Disease·Guanghua LuoNing Xu
Apr 23, 2015·Molecular Medicine Reports·Li-Zhu HuangYao Zhang
Apr 17, 2008·Biochemical and Biophysical Research Communications·Xiaoying ZhangNing Xu
Nov 23, 2006·Transplantation Proceedings·X XuP Nilsson-Ehle
Mar 15, 2006·Current Opinion in Lipidology·Sophie Visvikis-Siest, Jean-Brice Marteau
May 9, 2006·Current Opinion in Lipidology·Björn Dahlbäck, Lars B Nielsen
Mar 19, 2016·Journal of Cellular and Molecular Medicine·Cecilia FrejBjörn Dahlbäck
Apr 17, 2019·International Journal of Molecular Sciences·Piero PingitoreStefano Romeo
Mar 30, 2019·Leukemia·Anair Graciela Lema FernandezCristina Mecucci
Aug 6, 2011·Biochimica Et Biophysica Acta·Jiang WeiNing Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.